SA Editor Brandy Betz
Contributor since: 2017
Kite Pharma Reports A Deadly First Quarter
The Trial Data That Sunk Aerie's Potential Market
Monday Movers: 3 Breaking Healthcare Stories That Will Have Long-Term Impacts
AstraZeneca's New Drug: Too Little, Too Late?
Abbott's First Quarter: Medical Device Segment Grows Over 100%
BioMarin Races Towards Next Rare Disease Approval
Key Data To Watch In Abbott's First Quarter Report
Exact Sciences: Buy Now On Coverage Expansion?
Were Investors Right To Flee Ultragenyx After Trial Result Failure?
Kite Pharma: Still Time To Get In Ahead Of Lead Oncology Treatment Approval
Endpoint Watch: Merck, Pfizer Up For December Diabetes Drug Approvals In U.S., Europe
Tuesday's Healthcare Sinkers: Why Did Shares Of Analogic Corp, Loxo Oncology And Ionis Pharma Drop?
3 Things To Know Ahead Of Aerie Pharmaceuticals' Q4 Report
Industry Snapshot: Setting Sights On Glaucoma Drug Makers
Investor's Guide To Clinical Trials: Phase Success Rates For Introductory Pipeline Analysis
Gilead Sciences Will More Than Survive 2017
Patent Cliff, Blockbuster Drug, Shaky Pipeline: Should Bulls Run To Merck?
3 Reasons Q4 Made McDonald's A Hold
Zynga's Wheezing Ahead Of Dawn Of Titans Metrics